Vaccine Research Update – 26 June 2026: Dengue, HIV, COVID-19, Cancer Vaccines and More

This biweekly Vaccine Research video recap highlights regulatory actions, clinical progress, therapeutic vaccine advances, safety monitoring, and platform investment. 🔬 Key highlights: 🦟 Brazil pauses Butantan-DV dengue vaccine rollout 🧬 HK–Shenzhen therapeutic HIV vaccine shows early viral-control signals 🛡️ Invivyd completes Phase 3 LIBERTY enrollment for VYD2311 🎗️ CellxLife licenses Mayo Clinic FRα ovarian cancer vaccine 👧 FDA expands Merck Capvaxive pediatric indication 🌍 LASSARAB shows first-in-human Lassa and rabies immunogenicity 🫁 Transgene initiates TG4070 Phase 1 trial in resected NSCLC 💼 South Korea selects Premier Partners for K-Bio·Vaccine Fund No. 7 Chapters: 0:00 Introduction 0:08 Brazil pauses Butantan-DV dengue vaccine rollout 0:27 HK–Shenzhen therapeutic HIV vaccine shows early viral-control signals 0:48 Invivyd completes Phase 3 LIBERTY enrollment for VYD2311 1:11 CellxLife licenses Mayo Clinic FRα ovarian cancer vaccine 1:29 FDA expands Merck Capvaxive pediatric indication 1:52 LASSARAB shows first-in-human Lassa and rabies immunogenicity 2:12 Transgene initiates TG4070 Phase 1 trial in resected NSCLC 2:33 South Korea selects Premier Partners for K-Bio·Vaccine Fund No. 7 2:52 How to reach us 📢 Stay Ahead in Vaccine Research! ✅ Like, share, and subscribe for future updates on Vaccine Research ✅ Visit www.lqventures.com for expert healthcare insights and consulting services. ✅ Contact LucidQuest at info@lqventures.com for strategic guidance on Vaccine Research innovations and clinical research. 🔔 Turn on notifications so you never miss an update! #VaccineResearch #DengueVaccine #HIVVaccine #COVID19 #CancerVaccines #PneumococcalVaccine #LassaFever #RabiesVaccine #NSCLC #ClinicalTrials #FDA #LucidQuest